TTX-3360

TTX-3360 is an investigational **antisense oligonucleotide** developed by **Triplet Therapeutics** for **Huntington's disease** and potentially other repeat expansion disorders. The drug is designed to reduce expression of **MSH3**, a DNA mismatch repair protein in the DNA damage response pathway that contributes to somatic expansion of pathogenic CAG repeats. By lowering MSH3 expression, TTX-3360 is intended to slow or halt repeat expansion biology believed to drive disease progression in Huntington's disease. Reported preclinical work showed durable knockdown in relevant brain regions after **intracerebroventricular administration**, supporting development in presymptomatic and early manifest Huntington's disease, with broader potential across other central nervous system repeat expansion disorders.